Nathan Price earned his B.S. in
chemical engineering from
BYU, followed by M.S. and PhD in
bioengineering from the
University of California, San Diego. Following his doctoral studies, he completed postdoctoral research at the
Institute for Systems Biology (ISB). He later joined the faculty at ISB, becoming a professor and serving as an associate director. At ISB, he collaborated with biotechnology pioneer
Leroy Hood, co-directing the Hood-Price Lab for
Systems Biomedicine. He was also a co-PI of ISB’s
100K Wellness Project during his tenure. Prior to that he was an assistant professor at the
University of Illinois, Urbana-Champaign in Chemical & Biomolecular Engineering and at the Institute for Genomic Biology. Price has also been active in the commercial sector. He is the chief scientific officer at Thorne HealthTech. Prior to this role, he was the CEO of Onegevity, an AI health intelligence company that subsequently merged with Thorne. He was also a co-founder of the personalized health company Arivale. He is an elected fellow of the
American Institute for Medical and Biological Engineering and has been recognized as a Camille Dreyfus Teacher-Scholar. Price has held leadership roles in scientific bodies, including serving as chair of the
National Institutes of Health (NIH) Study Section on Modeling and Analysis of Biological Systems (MABS) from 2018 to 2020, and member of National Academy of Medicine committee to review omics-based tests for clinical trials. He has also served on numerous advisory boards including for
Roche (Personalized Healthcare Division),
Providence St. Joseph Health,
Basepaws, the
Novo Nordisk Foundation Center for Biosustainability and many others. He also served on the board of trustees of the Health and Environmental Sciences Institute and the
American Cancer Society (ACS) board of advisors (WA). == Research ==